ABVX Valuation Metrics
FCF$-189.73M
FCF Growth Rate—
EPS Growth (CAGR)—
WACC10.00%
Abivax
Exchange: NASDAQSector: HealthcareIndustry: Biotechnology
Values in USD · ADR · Reports in EUR
Abivax
Current Price
$119.90
+5.43%Profile
Valuation (TTM)
Market Cap$8.75B
P/E-22.42
EV—
P/B16.33
Shares Out72.94M
P/Sales1654.10
Revenue$5.29M
EV/EBITDA—
Abivax (ABVX) Valuation
Fair Value Models
Graham Number, PEG-based, and Earnings-based models
View Fair Value →ABVX Valuation & Fair Value Analysis
Abivax (ABVX) valuation analysis using multiple fair value methodologies. GoodMoat calculates a blended fair value target using discounted cash flow (DCF) analysis, the Graham Number, and earnings-based valuation models.
The price-to-earnings (P/E) ratio is -22.42. Price-to-book ratio is 16.33. Price-to-sales ratio is 1654.10. PEG ratio is -0.36.
GoodMoat's valuation models include the Graham Number (based on EPS and book value), an earnings-based model (discounted future EPS), and a PEG-adjusted valuation. The three models are averaged to produce a blended fair value estimate. Use these tools alongside the DCF calculator and reverse DCF to form a comprehensive view of Abivax's intrinsic value.